🚀 VC round data is live in beta, check it out!
Proteomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Proteomics and similar public comparables like Genoway, Bio-Works Technologies, Carelabs, Beamtree and more.
Proteomics Overview
About Proteomics
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Founded
2014
HQ
Employees
N/A
Website
Financials (LTM)
EV
$28M
Proteomics Financials
Proteomics reported last 12-month revenue of $2M and negative EBITDA of ($5M).
In the same LTM period, Proteomics generated $2M in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).
Revenue (LTM)
Proteomics P&L
In the most recent fiscal year, Proteomics reported revenue of $2M and EBITDA of ($5M).
Proteomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | $685K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | (214%) | XXX | (214%) | XXX | XXX | XXX |
| EBIT Margin | (231%) | XXX | (231%) | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (232%) | XXX | (232%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Proteomics Stock Performance
Proteomics has current market cap of $34M, and enterprise value of $28M.
Market Cap Evolution
Proteomics' stock price is $0.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $34M | 3.0% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProteomics Valuation Multiples
Proteomics trades at 12.5x EV/Revenue multiple, and (5.8x) EV/EBITDA.
EV / Revenue (LTM)
Proteomics Financial Valuation Multiples
As of April 21, 2026, Proteomics has market cap of $34M and EV of $28M.
Equity research analysts estimate Proteomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Proteomics has a P/E ratio of (6.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34M | XXX | $34M | XXX | XXX | XXX |
| EV (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV/Revenue | 12.5x | XXX | 12.5x | XXX | XXX | XXX |
| EV/EBITDA | (5.8x) | XXX | (5.8x) | XXX | XXX | XXX |
| EV/EBIT | (5.4x) | XXX | (5.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 12.5x | XXX | 41.5x | XXX | XXX | XXX |
| P/E | (6.4x) | XXX | (6.4x) | XXX | XXX | XXX |
| EV/FCF | (6.4x) | XXX | (6.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Proteomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Proteomics Margins & Growth Rates
Proteomics' revenue in the last fiscal year grew by 4%.
Proteomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | (214%) | XXX | (214%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 193% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 363% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Proteomics Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Proteomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genoway | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Works Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Carelabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| Data Horizon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Proteomics M&A Activity
Proteomics acquired XXX companies to date.
Last acquisition by Proteomics was on XXXXXXXX, XXXXX. Proteomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Proteomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProteomics Investment Activity
Proteomics invested in XXX companies to date.
Proteomics made its latest investment on XXXXXXXX, XXXXX. Proteomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Proteomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Proteomics
| When was Proteomics founded? | Proteomics was founded in 2014. |
| Where is Proteomics headquartered? | Proteomics is headquartered in Australia. |
| Is Proteomics publicly listed? | Yes, Proteomics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Proteomics? | Proteomics trades under PIQ ticker. |
| When did Proteomics go public? | Proteomics went public in 2015. |
| Who are competitors of Proteomics? | Proteomics main competitors are Genoway, Bio-Works Technologies, Carelabs, Beamtree. |
| What is the current market cap of Proteomics? | Proteomics' current market cap is $34M. |
| What is the current revenue of Proteomics? | Proteomics' last 12 months revenue is $2M. |
| What is the current EV/Revenue multiple of Proteomics? | Current revenue multiple of Proteomics is 12.5x. |
| Is Proteomics profitable? | No, Proteomics is not profitable. |
| What is the current EBITDA of Proteomics? | Proteomics has negative EBITDA and is not profitable. |
| What is Proteomics' EBITDA margin? | Proteomics' last 12 months EBITDA margin is (214%). |
| What is the current EV/EBITDA multiple of Proteomics? | Current EBITDA multiple of Proteomics is (5.8x). |
| What is the current FCF of Proteomics? | Proteomics' last 12 months FCF is ($4M). |
| What is Proteomics' FCF margin? | Proteomics' last 12 months FCF margin is (194%). |
| What is the current EV/FCF multiple of Proteomics? | Current FCF multiple of Proteomics is (6.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.